Current existing therapies for prostate cancer eradicate the majority of cells within a tumor. However, most patients with advanced cancer still progress to androgen-independent metastatic disease that remains essentially incurable by current treatment strategies. Recent evidence has shown that cancer stem cells (CSCs) are a subset of the tumor cells that are responsible for initiating and maintaining the disease. Understanding normal stem cells and CSCs may provide insight into the origin of and new therapeutics for prostate cancer. Normal stem cells and CSCs have been identified in prostate tissue by the use of several markers or techniques. Although research on stem cells has been limited by the lack of suitable in vitro systems, recent studies show that not only primary cells but also several established cell lines may exhibit stem cell properties. This review discusses various in vitro culture systems to propagate normal prostate stem cells and prostate CSCs together with molecular markers. These in vitro cell culture models should be useful for elucidating the differentiation of prostatic epithelium and the biological features of prostate cancer.
Introduction
Prostate cancer is the most common male malignancy in the Western world. 1 Localized disease can be cured by surgery and radiation therapy. The therapy most widely used against advanced disease is androgen ablation and, initially, it almost always produces objective clinical responses. However, most patients eventually relapse with ablation-resistant prostate cancer and develop metastatic disease; currently, there is no treatment that will cure progressive hormone-refractory metastatic prostate cancer. The mechanisms of progression of prostate cancer have been extensively studied, yet are poorly understood. To explain these mechanisms and the heterogeneity in prostate cancer, one of the concepts that has evolved is that cancer arises from the neoplastic transformation of normal prostatic epithelial stem cells or transit amplifying cells. 2 Based on this stem cell model, understanding the stages of cell differentiation in normal prostate epithelium is essential for the identification of cells that are involved in prostate carcinogenesis and ablation-resistant prostate cancer.
Prostate epithelial stem cells
Prostatic epithelium is composed of two morphologically defined components, the basal and luminal layers, and three types of cells, basal, secretory and neuroendocrine cells. The different prostatic epithelial cells can be distinguished based on their localization, morphology and their phenotypic characteristics. Luminal secretory cells express androgen receptor (AR), prostate-specific antigen (PSA), prostatic acid phosphatase, CD57 3 and a low molecular weight cytokeratin, such as Keratin (K) 8 and K18. On the other hand, basal cells are non-secretory and display CD44, 3 p63, 4 a high molecular weight cytokeratin-such as K5 and K14, but not AR-PSA and prostatic acid phosphatase. Secretory cells are dependent on androgen for survival, but basal cells are independent. Some cells exhibit a keratin pattern intermediate between that of basal and luminal cells with expression of K5, K8 and K18 but not K14. Normal prostatic epithelial stem cells have been demonstrated to exist in the basal component. 5, 6 Isaacs and Coffey 6 proposed that androgen-independent stem cells give rise to two types of cells: stem cells and androgen-independent transit amplifying cells, which can divide rapidly with limited proliferative capacity and can differentiate into luminal cells through an intermediate phenotype.
Neuroendocrine cells are distributed throughout the basal and luminal layers and express chromogranin A and a variety of peptide hormones, but lack AR and PSA. 7, 8 Neuroendocrine cells are also thought to arise from dendritic cells rather than from epithelial stem cells and have a complex expression pattern of basal and luminal markers. 7 They appear to play a role in growth and differentiation, but their function is largely unknown. 8 To date, several putative stem cell populations have been identified as prostate stem cells by means of clonal assay, identification of several cell surface markers or side population (SP) analysis.
Prostate cancer stem cells
Both somatic stem cells and cancer stem cells (CSCs) have the capacity for organogenesis, but somatic stem cells generate normal tissues and tumor stem cells generate tumor tissues. Normal tissues arise from stem cells that grow and differentiate to create progenitor and mature cell populations. CSCs theory postulates that CSCs are a functional definition, that is, that a cell or a population of cells expresses a putative stem cell marker does not mean at all that this cell is a stem cell. For normal stem cells, the most important standard is that the cell can engage a multilineage repopulation of a tissue or organ. The most crucial standard for a CSC is its ability to re-initiate a serially transplantable tumor that recapitulates the original heterogeneity and tumor histology. 9, 10 Using this gold standard, many so-called prostate CSCs reported so far are based on correlative studies rather than being true CSCs. 11, 12 The current postulate of CSCs theory is that tumors contain a small population of stem-like cells, which are often called CSCs or tumor-initiating cells. In fact, recent evidence suggests that many tumors may actually arise from the transformation of progenitor cells rather than stem cells. The first evidence for CSCs has been shown in the context of acute myeloid leukemia. 13, 14 This principle has also been implicated in solid tumors, such as brain tumor, 15 breast cancer 16 and prostate cancer. 11 Initially, cancer was thought to be a homogeneous mass, which consisted of highly proliferative cells as a stochastic model, and most cancer treatment was designed to eliminate these cells. Based on CSC theory, CSCs are biologically distinct from non-CSCs in the overall population and are thought to be resistant to conventional chemotherapy or radiation therapy. Most prostate cancer cells express AR and PSA, and this phenotype mimicking luminal cells has been reported. AR signaling in luminal cells not only regulates PSA expression, but it is also required for survival, and this requirement is maintained in early cancers. Therefore, AR has a crucial role in the progression and treatment of prostate cancer. AR activity has been investigated in a number of cell lines or animal models as a main target of therapeutics in prostate cancer. It has been postulated that many mechanisms, including AR gene amplification or AR gene mutations, may promote the growth of ablation-resistant prostate cancer cells. 17 However, the mechanism of this progression still remains elusive. In fact, the majority of men will eventually have a relapse to an ablation-resistant state, yet androgen ablation therapy remains the primary therapy for patients with metastatic prostate cancer. Although prostate cancer cells usually express AR, AR expression is heterogenous in most primary prostate cancers and their metastases. 18 Understanding this heterogeneity is a key to elucidate prostate cancer progression and to develop the future treatment paradigms, it may support, in part, the CSCs theory in the prostate. Several recent studies have postulated the existence of CSCs in the prostate using primary prostate cancer cells, 11 prostate cancer cell lines 12, 19, 20 or animal models. 21, 22 However, this hypothetical model for the hierarchical organization of prostate cancer cells remains unproven because of the lack of appropriate in vitro and in vivo models.
Prostate stem cell markers
Numerous methods have been reported to identify the normal stem cells/CSCs.
Stem cells can be identified based on their expression and/or lack of cell surface markers or the exclusion of Hoechst 33342 (SP analysis) in both normal and cancer tissues.
Cell surface markers
Since markers that can identify stem cells in one organ/ tumor are not always useful to isolate stem cells in another organ/cancer, we need to investigate and select the appropriate stem cell markers for each organ/tissue. CD34 has been used as a critical marker for hematopoietic stem cells, 23, 24 since it was expressed on a subpopulation of human bone marrow cells. 25 CD44 has generated recent interest as a potential marker of human breast CSCs. 16 
Side population
In addition to using the cell surface markers, alternative methods to identify stem cells have been developed. The most promising of these alternative methods is termed the 'SP' assay. The SP forms a distinct population defined by its ability to pump out the DNA-binding dye Hoechst 33342. 34 The ATP-binding cassette (ABC) transporter ABCG2, which functions as the efflux activity of a group of drug-resistance pump proteins, has been identified as the molecular determinant of the SP phenotype. 35 SP cells in bone marrow were found to have a long-term reconstituting ability and to be hematopoietic stem cells. 34 Recently, this method has been utilized to identify the SP fraction in various kinds of normal adult tissues including umbilical cord blood, 36 skeletal muscle, 37 Models of normal and cancer stem cells in prostate J Miki and JS Rhim mammary gland, 38 lung, 39 brain, 40 liver 41 and prostate. 42 The SP fraction has been identified in human neuroblastoma, 43 and it was further shown that not only did the rat glioma C6 cell lines maintain cells with SP characteristics but also that the SP alone were capable of regenerating tumors in mice. 44 In the prostate, SP analysis has been used to identify the sub-population with stem cell properties in normal prostatic epithelial cells 42 and prostate cancer cells.
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In vitro culture systems 45, 46 On the other hand, cell lines are widely used in many aspects of research as the most common in vitro culture model, because they have a big advantage in being easy to handle for their infinite reproducible quantities. 47 So far, most of the human prostate cancer cell lines have been established from metastatic lesions or from xenograft tumors.
48, 49 Numerous attempts to establish human primary prostate cancer cell lines and human prostate epithelial cell lines have been undertaken with chemicals, a viral oncogene or the overexpression of the human telomerase catalytic subunit (hTERT). 47, 49 Despite extensive work on the development of many human prostate cancer cell lines, the proportion of patient samples that give rise to immortalized prostate cancer cell lines is still disappointingly low.
Cell culture systems for normal stem cells/CSCs
Several transgenic mouse models for prostate cancer as well as for prostatic differentiation have been developed. 21, 22 The transgenic adenocarcinoma mouse prostate model of prostate cancer contributes to our understanding of cancer biology and offers a very useful and important tool to study normal stem cells and CSCs.
The results obtained using this mice model suggested that Sca-1 (stem cell antigen-1) can be used to enrich prostate-regenerating cells that have multiple stem/ progenitor cell properties and can serve as targets for prostate carcinogenesis. However, several mechanisms or signalings seem to be different between mouse and human.
In normal stem cell and CSC studies, using primary cells carries the advantage that the cells indeed represent the original features of the tissue. Human primary tumor specimens have been used for most of the studies of CSCs including those from brain tumors, 15 ,50,51 breast cancer, 16 pancreatic cancer 52 and prostate cancer. 11 However, there are still some difficulties. These include the limited access to biopsy materials, the need for the exclusion of contamination by cancer or normal cells, the short lifespan of cells and the small population of the putative stem cells (less than 1%). To circumvent these obstacles, an appropriate in vitro model is essential.
There is a possibility that the immortalized cell lines also contain differentiated cell functions similar to those of the original tissues. In fact, it has been reported that some human mammary epithelial immortalized cell lines exhibited stem-cell-like characteristics and could be used as models of normal breast morphogenesis. 53, 54 Although it has been suggested that the study of CSCs should be performed using primary cancer cells rather than cancer cell lines, 55 recent evidence using SP analysis 43, 44, 56 and cell surface marker, such as CD133, [57] [58] [59] or clonal analysis, 60, 61 shows that long-term cultured cell lines may retain a hierarchical proliferation or differentiation pattern as a potential of CSCs.
Recent studies with prostate cells have also shown that non-malignant-immortalized cell lines and malignant cell lines may contain a sub-population of cells with stem cell properties. The following section describes several in vitro culture systems including primary cells, immortalized cell lines and cancer cell lines ( 67 It has also been shown that SP cells, which account for approximately 1% of prostate epithelial cells reveal some stem cell properties such as a preponderance of quiescent G 0 cells or the expression of a2-integrin. 42 As it has been suggested that CSCs share properties with benign or normal stem cells, it is thought that cancer and normal stem cells can be purified with the same makers. In experiments with primary cell culture systems, only CD133 has been used as a stem cell marker to identify prospectively the CSCs in prostate tissue/cell lines.
11 Approximately, 0.1% of cells from 40 primary and metastatic prostate cancer tissues was identified with a CD44 þ /integrin a2b1 high /CD133 þ phenotype. These cells possessed a significant capacity for self-renewal and were also able to differentiate into cells expressing AR and prostatic acid phosphatase in vitro. However, it has not yet been shown whether the putative CSCs, CD133 þ cells, have a higher tumorigenicity in mice than non-CSCs, CD133
À cells.
Immortalized HPE cells and prostate cancer cell lines
Recent evidence suggests that CSCs may be present in several immortalized HPE or prostate cancer cell lines in in vitro culture systems even when they have been maintained for a long time.
HPV18-immortalized HPE cells. RWPE-1 cells immor-
talized with human papillomavirus 18 are non-tumorigenic human prostate epithelial cell lines. 68 Two clones, WPE-stem and WPE-int, were isolated from RWPE-1 cells. Compared to WPE-int cells, WPE-stem cells appeared to be similar to the UGS-stem/progenitor cells, because they expressed high levels of p63 and CK5/14 and low levels of CK18 and AR. They possessed a higher cloning efficiency and expressed higher matrix metalloproteinase-2 (MMP-2) activity. 69 hTERT-immortalized HPE cells. Telomerase is an enzyme responsible for replicating the telomere and is composed of an RNA subunit containing an integral catalytic subunit hTERT. It has been reported that hTERT overexpression maintains many characteristics of the corresponding parental cells. 70 hTERT-immortalized non-malignant HPE cell lines have been reported as a suitable model to study transformation of prostate cells and the stem cell origins of prostate cancer. hTERT-immortalized HPE cells mainly exhibited a basal cell phenotype (CK5/14, CK7 and p63) and were able to differentiate into glandular buds in the three-dimensional culture. 71 We have recently demonstrated that hTERT-immortalized primary non-malignant (RC-165N/hTERT) and malignant (RC-92a/hTERT) 72 tumor-derived HPE cell lines retain stem cell properties with a CD133 12 The CD133 þ cells from these immortalized cell lines had high proliferative potential in vitro. To evaluate the ability of the CD133 þ cells, we analyzed two types of characteristics, phenotype and morphology. The CD133 þ cells from both cell lines were able to differentiate into an AR-positive phenotype. In three-dimensional culture (Matrigel), the CD133 þ cells from RC-165N/hTERT cells produced branched structures, whereas the CD133 þ cells from RC-92a/hTERT cells produced large irregular spheroids with fewer branched structures. Therefore, these results may reflect the parallels and the distinction between prostate epithelial stem cells and prostate CSCs. Interestingly, a higher expression level of CD133 in hTERT-immortalized cells (45% in RC92a/hTERT and 80% in RC165N/hTERT) distinguished them from their primary cells (40.5% in both cell lines). This high expression of CD133 was observed right after the cells overcame replicative senescence and was maintained during long-term culture. Ectopic hTERT expression may affect this alteration because the expression of telomerase is associated with stem cells. Further studies are needed to verify this phenomenon, but a possible explanation is that hTERT appears to be activated more selectively in a small population of the CD133 þ cells. It may support the hypothesis that normal stem cells with the CD133 þ phenotype could be targeted for immortalization from CSCs initiated by telomerase activation. Nevertheless, further studies using animal models are needed to verify the tumorigenicity of these CD133 þ cells. Most recently, Gu et al. reported that clonally derived hTERT-immortalized prostate cancer cells (termed HPET shown that CSCs with the CD133 þ phenotype may also be present in many cancer cell lines such as hepatocellular carcinoma 58, 59 and laryngeal tumors. 57 In these reports, using animal studies, higher tumorigenicity of CD133 þ cells than CD133 -cells was demonstrated. CD44 is expressed in most basal cells in the normal prostate, but the involvement of CD44 in prostate cancer is still controversial. The heterogeneity in the expression of CD44 was examined in several prostate cancer cell lines. 19, 73 It has been reported that CD44 þ prostate cancer cells possess higher tumorigenicity than the CD44
À prostate cancer cells in Du145 cells and the cells from xenograft human tumors (LAPC-4 and LAPC-9). CD44 þ /ARÀ prostate cancer cells were also able to differentiate into AR þ cells. 19 SP cells have been isolated not only from primary tumor cells 43 but also from several tumor cell lines, including neuroblastoma, 43 breast cancer, 43 lung cancer, 43 gastrointestinal system tumor, 74 hepatocellular carcinoma, 75 nasopharyngeal carcinoma 76 and prostate cancer. 20 Patrawala et al. surveyed five human prostate cancer cells LNCaP, LAPC-9, Du145, PC3 and PPC-1. They only detected a distinct SP (0.07%) in xenograft tumor LAPC-9 cells. SP cells from LAPC-9 cells possessed 100-to 1000-fold higher tumorigenicity in non-obese diabetic/severe combined immunodeficiency mice than the corresponding non-SP cells, and the SP cells expressed some genes characteristic of stem cells. 20 However, it is not clear whether the SP cells have a potential for differentiation and also whether the SP cells from primary prostate cancer cells posses higher tumorigenicity. In addition, these two cell lines, LAPC-4 and LAP-C9, are derived from human prostate cancer xenograft tumors that have not been cultured in vitro.
Culture systems
The cultivation of stem cells has been limited by the lack of suitable systems that maintain these cells in an undifferentiated state. Traditionally, human embryonic stem cells have been cultured on mouse embryonic fibroblast feeder layers in media with serum, which allows their continuous growth in an undifferentiated state. 77 However, a defined culture system under feederfree and serum-free conditions is desirable because the feeder layer and serum may contain unknown compounds and affect the reproducibility and robustness.
A major advance in adult stem cell culture was achieved when neural stem cells and mammary epithelial stem cells were able to generate non-adherent spherical clusters of cells, termed neurospheres 78 or mammospheres, 79 in serum-free medium conditions. These culture methods allow the cultivation of CSCs from brain tumor 80 and breast cancer. 81 Using a similar strategy, it was possible to grow normal human prostatederived immortalized cell line RWPE-1 as free-floating clusters of cells called 'prostaspheres'. 69 We also have described this prostaspheres culture system in which non-malignant and malignant human hTERT-immortalized prostate epithelial cells were able to maintain higher CD133 expression. 12 Despite the fact that more work using primary cells to show the multiple lineages from single cell needs to be carried out, these results suggest that the sphere culture methods can contribute to the identification of normal stem cells and CSCs from the prostate.
In contrast to these non-adherent sphere culture systems, the three-dimensional culture in Matrigel, which is widely used as the commercially available basement membrane, has been demonstrated to promote differentiation of prostate stem cells. 64 Culture on Matrigel was able to induce morphological and phenotypical differentiation in normal and malignant prostate epithelial cell lines. 82 In our study, using the Matrigel culuture system, differences in morphological differentiation potential between normal prostatic epithelial cells and prostate cancer cells could be demonstrated. 12 The In vitro Matrigel three-dimensional culture system may provide a useful model for studying differentiation of normal stem cells and CSCs in prostate.
Issues for identifying CSCs
To verify the identification of CSCs from human solid tumors, the following techniques are required. First, a single cell suspension is prepared from a tumor with enzymatic digestion or explant culture method. Second, the cells are sorted/identified based on the expression and/or lack of surface molecular markers or the exclusion of Hoechst 33342 (SP analysis). Third, the sorted cells are inoculated into immunodeficient mice to determine the tumor-producing ability at various levels of these putative CSCs and non-CSCs. 83 However, we need to understand that there are many difficulties and uncertainties in every step of the above techniques.
In the process of preparing primary cells, it is very difficult to isolate only tumor cells, especially in prostate cancer tissues, because tumor tissues contain both tumor and normal cells, the tumor size is small, the tumor location is invisible and the tumor distribution in the prostate is random. There are currently no specific markers to distinguish the normal prostatic epithelial cells from prostate cancer cells. In addition, primary cell cultures derived from prostate cancer as well as normal prostatic epithelial cells show the basal phenotype, even though prostate cancers lack cells with a basal phenotype, mostly expressing luminal makers, such as AR and PSA. The plasticity of cytokeratin expression and the existence of some other elements, including stromal cells, a basal membrane, growth factor or hormone, may be related to this finding, 45 ) serum-free, growth factor-defined medium is widely used for the primary culture of prostate cells. As has been reported previously, CD133 þ cells from primary malignant tumors have the risk of being contaminated with non-malignant CD133 þ cells because low-calcium serum-free defined medium selects against prostate cancer cells. 67 We need to establish the appropriate in vitro culture system for both normal stem cells and caner stem cells from the prostate. The use of cancer cell lines may reduce or clear the risk of contamination. In fact, as pointed out before, since the gold standard for judging a CSC is in vivo tumor development, potential contamination of CSCs by normal stem cells should not constitute a major problem. On the other hand, contamination of normal stem cells by potential CSCs should also be easy to differentiate, because true CSCs will certainly have problem in development.
As SP cells are known to be heterogeneous, a real stem cell population can be composed of heterogeneous subpopulations. It might be worth considering combining cell-surface markers with SP analysis or another method to identify a more accurate stem cell population.
It is very crucial to perform in vivo experiments to show that the cancer-derived CD133 þ cells, but not CD133 À cells, give rise to cancer in immunodeficient mice, to verify the tumor-producing ability of these putative CSCs. It has been reported that CD133
þ CSCs in prostate demonstrated a higher proliferative potential in an in vitro culture system. 11, 12 Furthermore, CSCs and somatic stem cells exploit many of the same signal pathways, such as Notch, Wnt and Sonic hedgehog, to play important roles in self-renewal, proliferation and differentiation. 84, 85 The efforts to elucidate these pathways should be performed on both normal stem cells and CSCs, and thus it might be possible to develop the novel therapeutics that are effective against otherwise incurable cancers.
Although in vitro models have been shown in previous studies to be useful for understanding cellular biological functions including stem cell properties, it is necessary to understand that using in vitro models can suffer from several disadvantages. First of all, in vitro assays cannot replicate in vivo conditions exactly. Next, considering that gene alterations are often involved in cell proliferation, apoptosis and DNA repair during the immortalization process or in long-term culture, there are likely to be various biases of cell lines in many areas of research, not only in stem cell research. Finally, the properties of the cell lines do not always resemble properties of cells derived from the same organ. The in vitro cultured cells often lose their original differentiated function. It remains unclear whether cancer cell lines will be organized in a hierarchy of cells with tumorigenicity and differentiation potential, because each prostate cancer cell line has unique characteristics in terms of phenotype, tumorigenicity, cell kinetics, and so on. Indeed, the population of SP 20 and the expression pattern of cell surface markers 19, 73 are variable in several prostate cancer cell lines. The characteristics have been well studied in the prostate cancer cell lines and in primary cells, but the mechanisms of these variations are still elusive. Nevertheless, there is vast potential in using in vitro models if we select the appropriate cell lines or primary cells for certain aspects of stem cell research.
Conclusion
CSCs theory has now emerged as an innovative theory within the field of cancer biology, especially regarding solid tumors. It will be very important to show the existence of normal stem cells and CSCs in prostate tissue. Although cell lines have some disadvantages or shortcomings compared to primary cells, in vitro culture systems, including primary cells, immortalized cell lines and cancer cell lines, may contain a heterogeneous and hierarchical sub-population. Thus, the development of in vitro culture systems not only provides a useful novel tool for understanding key molecular pathways in prostate epithelial differentiation and prostate cancer progression, but also may have important implications for biological and pharmacological functions. We hope that the development of these culture models will lead to the identification of actual CSCs as a new therapeutic target to improve anticancer strategies. Primary cells, immortalized cells or cancer cell lines as in vitro models of normal stem cells and CSCs in the prostate may provide insight into the mechanisms of prostate cancer development.
